Acute myeloid leukemia

New strategies to treat AML: novel insights into AML survival pathways and combination therapies

Abstract

The effective treatment of acute myeloid leukemia (AML) is very challenging. Due to the immense heterogeneity of this disease, treating it using a “one size fits all” approach is ineffective and only benefits a subset of patients. Instead, there is a shift towards more personalized treatment based on the patients’ genomic signature. This shift has facilitated the increased revelation of novel insights into pathways that lead to the survival and propagation of AML cells. These AML survival pathways are involved in drug resistance, evasion of the immune system, reprogramming metabolism, and impairing differentiation. In addition, based on the reports of enhanced clinical efficiencies when combining drugs or treatments, deeper investigation into possible pathways, which can be targeted together to increase treatment response in a wider group of patients, is warranted. In this review, not only is a comprehensive summary of targets involved in these pathways provided, but also insights into the potential of targeting these molecules in combination therapy will be discussed.

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

Fig. 1: Graphical summary of novel insights into pathways that contribute to AML survival.

References

  1. 1.

    Shallis RM, Wang R, Davidoff A, Ma X, Zeidan AM. Epidemiology of acute myeloid leukemia: Recent progress and enduring challenges. Blood Rev. 2019;36:70–87.

    Article  Google Scholar 

  2. 2.

    Döhner H, Weisdorf DJ, Bloomfield CD. Acute myeloid leukemia. N Engl J Med. 2015;373:1136–52.

    Article  CAS  Google Scholar 

  3. 3.

    Eleni LD, Nicholas ZC, Alexandros S. Challenges in treating older patients with acute Myeloid Leukemia. J Oncol. 2010;2010:11.

    Article  CAS  Google Scholar 

  4. 4.

    Hassan C, Afshinnekoo E, Li S, Wu S, Mason CE. Genetic and epigenetic heterogeneity and the impact on cancer relapse. Exp Hematol. 2017;54:26–30.

    Article  Google Scholar 

  5. 5.

    Lohse I, Statz-Geary K, Brothers SP, Wahlestedt C. Precision medicine in the treatment stratification of AML patients: challenges and progress. Oncotarget. 2018;9:37790–7.

    Article  Google Scholar 

  6. 6.

    Tiong IS, Wei AH. New drugs creating new challenges in acute myeloid leukemia. Genes Chromosom Cancer. 2019;58:903–14.

    CAS  Article  Google Scholar 

  7. 7.

    Lai C, Doucette K, Norsworthy K. Recent drug approvals for acute myeloid leukemia. J Hematol Oncol. 2019;12:100.

    Article  CAS  Google Scholar 

  8. 8.

    Tyner JW, Tognon CE, Bottomly D, Wilmot B, Kurtz SE, Savage SL, et al. Functional genomic landscape of acute myeloid leukemia. Nature. 2018;562:526.

    CAS  Article  Google Scholar 

  9. 9.

    Cerrano M, Itzykson R. New treatment options for acute myeloid leukemia in 2019. Curr Oncol Rep. 2019;21:16.

    Article  Google Scholar 

  10. 10.

    Kang Y, Tran T, Zhang L, Ball ED, Piermarocchi C, Paternostro G. Personalized drug combinations for the treatment of acute myeloid leukemia (AML) patients. Blood 2014;124:3616.

    Article  Google Scholar 

  11. 11.

    Pollyea DA, Amaya M, Strati P, Konopleva MY. Venetoclax for AML: changing the treatment paradigm. Blood Adv. 2019;3:4326–35.

    Article  Google Scholar 

  12. 12.

    Winer ES, Stone RM. Novel therapy in Acute myeloid leukemia (AML): moving toward targeted approaches. Ther Adv Hematol. 2019;10:204062071986064.

    Article  CAS  Google Scholar 

  13. 13.

    Zhang J, Gu Y, Chen B. Mechanisms of drug resistance in acute myeloid leukemia. Onco Targets Ther. 2019;12:1937–45.

    Article  Google Scholar 

  14. 14.

    Teague RM, Kline J. Immune evasion in acute myeloid leukemia: Current concepts and future directions. J Immunother cancer. 2013;1:13.

    Article  Google Scholar 

  15. 15.

    Chapuis N, Poulain L, Birsen R, Tamburini J, Bouscary D. Rationale for targeting deregulated metabolic pathways as a therapeutic strategy in acute myeloid leukemia. Front Oncol. 2019;9:405.

    Article  Google Scholar 

  16. 16.

    Gocek E, Marcinkowska E. Differentiation therapy of acute myeloid leukemia. Cancers (Basel). 2011;3:2402–20.

    CAS  Article  Google Scholar 

  17. 17.

    Ross DD. Novel mechanisms of drug resistance in leukemia. Leukemia. 2000;14:467–73.

    CAS  Article  Google Scholar 

  18. 18.

    Schneider C, Oellerich T, Baldauf HM, Schwarz SM, Thomas D, Flick R, et al. SAMHD1 is a biomarker for cytarabine response and a therapeutic target in acute myeloid leukemia. Nat Med. 2017;23:250–5.

    Article  CAS  Google Scholar 

  19. 19.

    Herold N, Rudd SG, Ljungblad L, Sanjiv K, Myrberg IH, Paulin CBJ, et al. Targeting SAMHD1 with the Vpx protein to improve cytarabine therapy for hematological malignancies. Nat Med. 2017;23:256–63.

    CAS  Article  Google Scholar 

  20. 20.

    Kohnken R, Kodigepalli KM, Wu L. Regulation of deoxynucleotide metabolism in cancer: Novel mechanisms and therapeutic implications. Mol Cancer. 2015;14:176.

    Article  CAS  Google Scholar 

  21. 21.

    Knecht KM, Buzovetsky O, Schneider C, Thomas D, Srikanth V, Kaderali L, et al. The structural basis for cancer drug interactions with the catalytic and allosteric sites of SAMHD1. Proc Natl Acad Sci USA 2018;115:E10022–31.

    CAS  Article  Google Scholar 

  22. 22.

    Oellerich T, Schneider C, Thomas D, Knecht KM, Buzovetsky O, Kaderali L, et al. Selective inactivation of hypomethylating agents by SAMHD1 provides a rationale for therapeutic stratification in AML. Nat Commun. 2019;10:3475.

    Article  CAS  Google Scholar 

  23. 23.

    Mlcochova P, Caswell SJ, Taylor IA, Towers GJ, Gupta RK. DNA damage induced by topoisomerase inhibitors activates SAMHD 1 and blocks HIV -1 infection of macrophages. EMBO J. 2018;37:50–62.

    CAS  Article  Google Scholar 

  24. 24.

    Hofmann H, Logue EC, Bloch N, Daddacha W, Polsky SB, Schultz ML, et al. The Vpx lentiviral accessory protein targets SAMHD1 for degradation in the nucleus. J Virol. 2012;86:12552–60.

    CAS  Article  Google Scholar 

  25. 25.

    Burnett AK, Milligan D, Prentice AG, Goldstone AH, McMullin MF, Hills RK, et al. A comparison of low-dose cytarabine and hydroxyurea with or without all-trans retinoic acid for acute myeloid leukemia and high-risk myelodysplastic syndrome in patients not considered fit for intensive treatment. Cancer. 2007;109:1114–24.

    CAS  Article  Google Scholar 

  26. 26.

    Rudd SG, Tsesmetzis N, Sanjiv K, Paulin CB, Sandhow L, Kutzner J, et al. Ribonucleotide reductase inhibitors suppress SAMHD 1 ara‐ CTP ase activity enhancing cytarabine efficacy. EMBO Mol Med. 2020;12.

  27. 27.

    Matsuura K, Canfield K, Feng W, Kurokawa M. Metabolic regulation of apoptosis in cancer. Int Rev Cell Mol Biol. 2016;327:43–87.

    CAS  Article  Google Scholar 

  28. 28.

    Van Brocklyn JR, Williams JB. The control of the balance between ceramide and sphingosine-1-phosphate by sphingosine kinase: Oxidative stress and the seesaw of cell survival and death. Comp Biochem Physiol - B Biochem Mol Biol. 2012;163:26–36.

    Article  CAS  Google Scholar 

  29. 29.

    Gault CR, Obeid LM, Hannun YA. An overview of sphingolipid metabolism: from synthesis to breakdown. Adv Exp Med Biol. 2010;688:1–23.

  30. 30.

    Tan SF, Liu X, Fox TE, Barth BM, Sharma A, Turner SD, et al. Acid ceramidase is upregulated in AML and represents a novel therapeutic target. Oncotarget. 2016;7:83208–22.

    Article  Google Scholar 

  31. 31.

    Fordham SE, Matheson EC, Scott K, Irving JAE, Allan JM. DNA mismatch repair status affects cellular response to Ara-C and other anti-leukemic nucleoside analogs. Leukemia. 2011;25:1046–9.

    CAS  Article  Google Scholar 

  32. 32.

    Tan S-F, Dunton W, Liu X, Fox TE, Morad SAF, Desai D, et al. Acid ceramidase promotes drug resistance in acute myeloid leukemia through NF-κB-dependent P-glycoprotein upregulation. J Lipid Res. 2019;60:1078–86.

    CAS  Article  Google Scholar 

  33. 33.

    Dany M, Gencer S, Nganga R, Thomas RJ, Oleinik N, Baron KD, et al. Targeting FLT3-ITD signaling mediates ceramide-dependent mitophagy and attenuates drug resistance in AML. Blood. 2016;128:1944–58.

    CAS  Article  Google Scholar 

  34. 34.

    Kao L-P, Morad SAF, Davis TS, MacDougall MR, Kassai M, Abdelmageed N, et al. Chemotherapy selection pressure alters sphingolipid composition and mitochondrial bioenergetics in resistant HL-60 cells. J Lipid Res. 2019;60:1590–602.

    CAS  Article  Google Scholar 

  35. 35.

    Powell JA, Lewis AC, Zhu W, Toubia J, Pitman MR, Wallington-Beddoe CT, et al. Targeting sphingosine kinase 1 induces MCL1-dependent cell death in acute myeloid leukemia. Blood. 2017;129:771–82.

    CAS  Article  Google Scholar 

  36. 36.

    Ramsey HE, Fischer MA, Lee T, Gorska AE, Arrate MP, Fuller L, et al. A novel MCL1 inhibitor combined with venetoclax rescues venetoclax-resistant acute myelogenous Leukemia. Cancer Discov. 2018;8:1566–81.

    CAS  Article  Google Scholar 

  37. 37.

    Senchenkov A, Litvak DA, Cabot MC. Targeting ceramide metabolism—a strategy for overcoming drug resistance. J Natl Cancer Inst. 2001;93:347–57.

    CAS  Article  Google Scholar 

  38. 38.

    Toffalori C, Zito L, Gambacorta V, Riba M, Oliveira G, Bucci G, et al. Immune signature drives leukemia escape and relapse after hematopoietic cell transplantation. Nat Med Nat Publ Group. 2019;25:603–11.

    CAS  Article  Google Scholar 

  39. 39.

    Liao D, Wang M, Liao Y, Li J, Niu T. A review of efficacy and safety of checkpoint inhibitor for the treatment of acute myeloid leukemia. Frontiers in Pharmacology. Frontiers Media S.A.; 2019. vol. 10.

  40. 40.

    Deng M, Gui X, Kim J, Xie L, Chen W, Li Z, et al. LILRB4 signalling in leukaemia cells mediates T cell suppression and tumour infiltration. Nature. 2018;562:605–9.

    CAS  Article  Google Scholar 

  41. 41.

    Baitsch D, Bock HH, Engel T, Telgmann R, Müller-Tidow C, Varga G, et al. Apolipoprotein e induces antiinflammatory phenotype in macrophages. Arterioscler Thromb Vasc Biol. 2011;31:1160–8.

    CAS  Article  Google Scholar 

  42. 42.

    Gui X, Deng M, Song H, Chen Y, Xie J, Li Z, et al. Disrupting LILRB4/APOE interaction by an efficacious humanized antibody reverses T-cell suppression and blocks AML development. Cancer Immunol Res. 2019;7:1244–57.

    CAS  Article  Google Scholar 

  43. 43.

    John S, Chen H, Deng M, Gui X, Wu G, Chen W, et al. A novel anti-LILRB4 CAR-T cell for the treatment of monocytic AML. Mol Ther. 2018;26:2487–95.

    CAS  Article  Google Scholar 

  44. 44.

    Yang H, Bueso-Ramos C, Dinardo C, Estecio MR, Davanlou M, Geng QR, et al. Expression of PD-L1, PD-L2, PD-1 and CTLA4 in myelodysplastic syndromes is enhanced by treatment with hypomethylating agents. Leukemia. 2014;28:1280–8.

    CAS  Article  Google Scholar 

  45. 45.

    Daver N, Boddu P, Garcia-Manero G, Yadav SS, Sharma P, Allison J, et al. Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes. Leukemia. 2018;32:1094–105.

  46. 46.

    Kang X, Lu Z, Cui C, Deng M, Fan Y, Dong B, et al. The ITIM-containing receptor LAIR1 is essential for acute myeloid leukaemia development. Nat Cell Biol. 2015;17:665–77.

    CAS  Article  Google Scholar 

  47. 47.

    Maifrede S, Nieborowska-Skorska M, Sullivan-Reed K, Dasgupta Y, Podszywalow-Bartnicka P, Le BV, et al. Tyrosine kinase inhibitor–induced defects in DNA repair sensitize FLT3(ITD)-positive leukemia cells to PARP1 inhibitors. Blood. 2018;132:67–77.

    CAS  Article  Google Scholar 

  48. 48.

    Weaver AN, Yang ES. Beyond DNA repair: additional functions of PARP-1 in cancer. Front Oncol. 2013;3:290.

    Article  Google Scholar 

  49. 49.

    Yélamos J, Moreno-Lama L, Jimeno J, Ali SO. Immunomodulatory roles of PARP-1 and PARP-2: impact on PARP-centered cancer therapies. Cancers. 2020;12:392.

  50. 50.

    Aurelius J, Thorén FB, Akhiani AA, Brune M, Palmqvist L, Hansson M, et al. Monocytic AML cells inactivate antileukemic lymphocytes: Role of NADPH oxidase/gp91 phox expression and the PARP-1/PAR pathway of apoptosis. Blood 2012;119:5832–7.

    CAS  Article  Google Scholar 

  51. 51.

    Thorén FB, Romero AI, Hellstrand K. Oxygen radicals induce Poly(ADP-Ribose) polymerase-dependent cell death in cytotoxic lymphocytes. J Immunol. 2006;176:7301–7.

    Article  Google Scholar 

  52. 52.

    Nilsson MS, Hallner A, Brune M, Nilsson S, Thorén FB, Martner A, et al. Immunotherapy with HDC/IL-2 may be clinically efficacious in acute myeloid leukemia of normal karyotype. Hum Vaccines Immunother. 2020;16:109–11.

    CAS  Article  Google Scholar 

  53. 53.

    Gasser S, Orsulic S, Brown EJ, Raulet DH. The DNA damage pathway regulates innate immune system ligands of the NKG2D receptor. Nature 2005;436:1186–90.

    CAS  Article  Google Scholar 

  54. 54.

    Paczulla AM, Rothfelder K, Raffel S, Konantz M, Steinbacher J, Wang H, et al. Absence of NKG2D ligands defines leukaemia stem cells and mediates their immune evasion. Nature. 2019;572:254–9.

    CAS  Article  Google Scholar 

  55. 55.

    Carlsten M, Järås M. Natural killer cells in myeloid malignancies: immune surveillance, nk cell dysfunction, and pharmacological opportunities to bolster the endogenous NK cells. Front Immunol. 2019;10:2357.

  56. 56.

    Li X, Li C, Jin J, Wang J, Huang J, Ma Z, et al. High PARP-1 expression predicts poor survival in acute myeloid leukemia and PARP-1 inhibitor and SAHA-bendamustine hybrid inhibitor combination treatment synergistically enhances anti-tumor effects. EBioMed. 2018;38:47–56.

    Article  Google Scholar 

  57. 57.

    Molenaar RJ, Radivoyevitch T, Nagata Y, Khurshed M, Przychodzen B, Makishima H, et al. Idh1/2 mutations sensitize acute myeloid leukemia to parp inhibition and this is reversed by idh1/2-mutant inhibitors. Clin Cancer Res. 2018;24:1705–15.

    CAS  Article  Google Scholar 

  58. 58.

    Dellomo AJ, Baer MR, Rassool FV. Partnering with PARP inhibitors in acute myeloid leukemia with FLT3-ITD. Cancer Lett. 2019;454:171–8.

  59. 59.

    Gojo I, Beumer JH, Pratz KW, McDevitt MA, Baer MR, Blackford AL, et al. A phase 1 study of the PARP inhibitor veliparib in combination with temozolomide in acute myeloid leukemia. Clin Cancer Res. 2017;23:697–706.

    CAS  Article  Google Scholar 

  60. 60.

    Esposito MT, Zhao L, Fung TK, Rane JK, Wilson A, Martin N, et al. Synthetic lethal targeting of oncogenic transcription factors in acute leukemia by PARP inhibitors. Nat Med. 2015;21:1481–90.

    CAS  Article  Google Scholar 

  61. 61.

    Phan LM, Yeung SCJ, Lee MH. Cancer metabolic reprogramming: importance, main features, and potentials for precise targeted anti-cancer therapies. Cancer Biol Med. 2014;11:1–19.

  62. 62.

    Patra KC, Hay N. The pentose phosphate pathway and cancer. Trends Biochem Sci. 2014;39:347–54.

  63. 63.

    Reczek CR, Chandel NS. The Two Faces of Reactive Oxygen Species in Cancer. Annu Rev Cancer Biol. 2017;1:79–98.

    Article  Google Scholar 

  64. 64.

    Ribas V, García-Ruiz C, Fernández-Checa JC. Glutathione and mitochondria. Front Pharmacol. 2014;5:151.

  65. 65.

    Hole PS, Zabkiewicz J, Munje C, Newton Z, Pearn L, White P, et al. Overproduction of NOX-derived ROS in AML promotes proliferation and is associated with defective oxidative stress signaling. Blood. 2013;122:3322–30.

    CAS  Article  Google Scholar 

  66. 66.

    Hole PS, Pearn L, Tonks AJ, James PE, Burnett AK, Darley RL, et al. Ras-induced reactive oxygen species promote growth factor - Independent proliferation in human CD34+ hematopoietic progenitor cells. Blood. 2010;115:1238–46.

    CAS  Article  Google Scholar 

  67. 67.

    Jayavelu AK, Moloney JN, Böhmer FD, Cotter TG. NOX-driven ROS formation in cell transformation of FLT3-ITD-positive AML. Exp Hematol. 2016;44:1113–22.

  68. 68.

    Sengupta A, Arnett J, Dunn S, Williams DA, Cancelas JA. Rac2 GTPase deficiency depletes BCR-ABL+ leukemic stem cells and progenitors in vivo. Blood. 2010;116:81–4.

    CAS  Article  Google Scholar 

  69. 69.

    Pick E. Role of the Rho GTPase Rac in the activation of the phagocyte NADPH oxidase: outsourcing a key task. Small GTPases. 2014;5:e27952.

    Article  Google Scholar 

  70. 70.

    Aydin E, Hallner A, Grauers Wiktorin H, Staffas A, Hellstrand K, Martner A. NOX2 inhibition reduces oxidative stress and prolongs survival in murine KRAS-induced myeloproliferative disease. Oncogene. 2019;38:1534–43.

    CAS  Article  Google Scholar 

  71. 71.

    Adane B, Ye H, Khan N, Pei S, Minhajuddin M, Stevens BM, et al. The hematopoietic oxidase NOX2 regulates self-renewal of leukemic stem cells. Cell Rep. 2019;27:238–254.e6.

    CAS  Article  Google Scholar 

  72. 72.

    Prata C, Maraldi T, Fiorentini D, Zambonin L, Hakim G, Landi L. Nox-generated ROS modulate glucose uptake in a leukaemic cell line. Free Radic Res. 2008;42:405–14.

    CAS  Article  Google Scholar 

  73. 73.

    Bonello S, Zähringer C, BelAiba RS, Djordjevic T, Hess J, Michiels C, et al. Reactive oxygen species activate the HIF-1α promoter via a functional NFκB site. Arterioscler Thromb Vasc Biol. 2007;27:755–61.

    CAS  Article  Google Scholar 

  74. 74.

    Mucaj V, Shay JES, Simon MC. Effects of hypoxia and HIFs on cancer metabolism. Int J Hematol. 2012;95:464–70.

    CAS  Article  Google Scholar 

  75. 75.

    Marlein CR, Zaitseva L, Piddock RE, Robinson SD, Edwards DR, Shafat MS, et al. NADPH oxidase-2 derived superoxide drives mitochondrial transfer from bone marrow stromal cells to leukemic blasts. Blood. 2017;130:1649–60.

    CAS  Article  Google Scholar 

  76. 76.

    Moschoi R, Imbert V, Nebout M, Chiche J, Mary D, Prebet T, et al. Protective mitochondrial transfer from bone marrow stromal cells to acute myeloid leukemic cells during chemotherapy. Blood. 2016;128:253–64.

    CAS  Article  Google Scholar 

  77. 77.

    Pollyea DA, Stevens BM, Jones CL, Winters A, Pei S, Minhajuddin M, et al. Venetoclax with azacitidine disrupts energy metabolism and targets leukemia stem cells in patients with acute myeloid leukemia. Nat Med. 2018;24:1859–66.

    CAS  Article  Google Scholar 

  78. 78.

    Shi L, Pan H, Liu Z, Xie J, Han W. Roles of PFKFB3 in cancer. Signal Transduct Target Ther. 2017;2:17044.

    Article  Google Scholar 

  79. 79.

    Feng Y, Wu L. mTOR up-regulation of PFKFB3 is essential for acute myeloid leukemia cell survival. Biochem Biophys Res Commun. 2017;483:897–903.

    CAS  Article  Google Scholar 

  80. 80.

    Masoud GN, Li W. HIF-1α pathway: role, regulation and intervention for cancer therapy. Acta Pharma Sinica B. 2015;5:378–89.

  81. 81.

    Robinson AJ, Hopkins GL, Rastogi N, Hodges M, Doyle M, Davies S, et al. Reactive oxygen species drive proliferation in acute myeloid leukemia via the glycolytic regulator PFKFB3. Cancer Res. 2020;80:937–49.

    CAS  Article  Google Scholar 

  82. 82.

    Qian S, Li J, Hong M, Zhu Y, Zhao H, Xie Y, et al. TIGAR cooperated with glycolysis to inhibit the apoptosis of leukemia cells and associated with poor prognosis in patients with cytogenetically normal acute myeloid leukemia. J Hematol Oncol. 2016;9:128.

    Article  CAS  Google Scholar 

  83. 83.

    Degos L, Wang ZY. All trans retinoic acid in acute promyelocytic leukemia. Oncogene. 2001;20:7140–5.

  84. 84.

    Mughal TI, Ejaz AA, Foringer JR, Coiffier B. An integrated clinical approach for the identification, prevention, and treatment of tumor lysis syndrome. Cancer Treat Rev. 2010;36:164–76.

    Article  Google Scholar 

  85. 85.

    Löffler M, Jöckel J, Schuster G, Becker C. Dihydroorotat-ubiquinone oxidoreductase links mitochondria in the biosynthesis of pyrimidine nucleotides. Mol Cell Biochem. 1997;174:125–9.

    Article  Google Scholar 

  86. 86.

    Levine RL, Hoogenraad NJ, Kretchmer N. A review: Biological and clinical aspects of pyrimidine metabolism. Pediatr Res. 1974;8:724–34.

    CAS  Article  Google Scholar 

  87. 87.

    Sykes DB, Kfoury YS, Mercier FE, Wawer MJ, Law JM, Haynes MK, et al. Inhibition of dihydroorotate dehydrogenase overcomes differentiation blockade in acute myeloid leukemia. Cell. 2016;167:171–86.e15.

    CAS  Article  Google Scholar 

  88. 88.

    Wu D, Wang W, Chen W, Lian F, Lang L, Huang Y, et al. Pharmacological inhibition of dihydroorotate dehydrogenase induces apoptosis and differentiation in acute myeloid leukemia cells. Haematologica. 2018;103:1472–83.

    CAS  Article  Google Scholar 

  89. 89.

    Christian S, Merz C, Evans L, Gradl S, Seidel H, Friberg A, et al. The novel dihydroorotate dehydrogenase (DHODH) inhibitor BAY 2402234 triggers differentiation and is effective in the treatment of myeloid malignancies. Leukemia. 2019;33:2403–15.

    CAS  Article  Google Scholar 

  90. 90.

    Zhou J, Quah JY, Ng Y, Chooi J-Y, Toh SH-M, Lin B, et al. ASLAN003, a potent dihydroorotate dehydrogenase inhibitor for differentiation of acute myeloid leukemia. Haematologica. 2019. https://doi.org/10.3324/haematol.2019.230482.

  91. 91.

    Cao L, Weetall M, Trotta C, Cintron K, Ma J, Kim MJ, et al. Targeting of hematologic malignancies with PTC299, a novel potent inhibitor of dihydroorotate dehydrogenase with favorable pharmaceutical properties. Mol Cancer Ther. 2019;18:3–16.

    CAS  Article  Google Scholar 

  92. 92.

    Sykes DB. The emergence of dihydroorotate dehydrogenase (DHODH) as a therapeutic target in acute myeloid leukemia. Expert Opinion Ther Targets. 2018;22:893–8.

  93. 93.

    Vélez J, Hail N, Konopleva M, Zeng Z, Kojima K, Samudio I, et al. Mitochondrial uncoupling and the reprograming of intermediary metabolism in leukemia cells. Front Oncol. 2013;3:67.

    Article  Google Scholar 

  94. 94.

    Jóźwiak P, Forma E, Bryś M, Krześlak A. O-GlcNAcylation and metabolic reprograming in cancer. Front Endocrinol (Lausanne). 2014;5:145.

    Google Scholar 

  95. 95.

    Itkonen HM, Mills IG. N-linked glycosylation supports cross-talk between receptor tyrosine kinases and androgen receptor. PLoS ONE. 2013;8:e65016.

    CAS  Article  Google Scholar 

  96. 96.

    Wagner FF, Benajiba L, Campbell AJ, Weïwer M, Sacher JR, Gale JP, et al. Exploiting an asp-glu “switch” in glycogen synthase kinase 3 to design paralog-selective inhibitors for use in acute myeloid leukemia. Sci Transl Med. 2018;10:eaam8460.

    Article  CAS  Google Scholar 

  97. 97.

    Sexauer AN, Do B, Sykes DB. Loss of FLT3 sensitizes myeloid cells to differentiation Via DHODH inhibition. Blood. 2019;134(Supplement_1):2712–2712.

  98. 98.

    Estey E, Levine RL, Löwenberg B. Current challenges in clinical development of “targeted therapies”: the case of acute myeloid leukemia. Blood. 2015;125:2461–6.

    CAS  Article  Google Scholar 

  99. 99.

    Wei AH, Strickland SA, Hou JZ, Fiedler W, Lin TL, Walter RB, et al. Venetoclax combined with low-dose cytarabine for previously untreated patients with acute myeloid leukemia: Results from a phase Ib/II study. J Clin Oncol. 2019;37:1277–84.

    CAS  Article  Google Scholar 

  100. 100.

    DiNardo CD, Pratz K, Pullarkat V, Jonas BA, Arellano M, Becker PS, et al. Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia. Blood. 2019;133:7–17.

    CAS  Article  Google Scholar 

Download references

Acknowledgements

We apologize to colleagues whose work could not be cited due to space constraints. We thank Dr. Oliver T. Keppler for continuous support and Dr. Constanze Schneider for critical reading of the manuscript. HMB acknowledges funding from the Wilhelm-Sander Stiftung (2017.122.1). RN is supported by the graduate program Infection Research on Human Pathogens@MvPI at Max von Pettenkofer Institute, LMU. AS-I is supported by the Max Weber-Program of the State of Bavaria. Open Access funding enabled and organized by Projekt DEAL.

Author information

Affiliations

Authors

Corresponding author

Correspondence to Hanna-Mari Baldauf.

Ethics declarations

Conflict of interest

The authors declare that they have no conflict of interest.

Additional information

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Supplementary information

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Nair, R., Salinas-Illarena, A. & Baldauf, HM. New strategies to treat AML: novel insights into AML survival pathways and combination therapies. Leukemia (2020). https://doi.org/10.1038/s41375-020-01069-1

Download citation

Search